Evidence map›Paper›PMID 27209424›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2016

Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.

Su Hyun Lee, Seunggyun Ha, Hyun Joon An, Jae Sung Lee, Wonshik Han, Seock-Ah Im, Han Suk Ryu, Won Hwa Kim, Jung Min Chang, Nariya Cho and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Advances in PET/CT Imaging for Breast Cancer.Journal of clinical medicine · 2023
    Review
  3. Article
  4. Article
  5. Article
  6. Is (18)FDG uptake useful to decide on chemotherapy in ER+/HER2- breast cancer?European journal of nuclear medicine and molecular imaging · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Su Hyun LeeDepartment of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Seunggyun HaDepartment of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Hyun Joon AnDepartment of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Jae Sung LeeDepartment of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Wonshik HanDepartment of Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Seock-Ah ImDepartment of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Han Suk RyuDepartment of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Won Hwa KimDepartment of Radiology, Kyungpook National University Hospital, Daegu, South Korea.
Jung Min ChangDepartment of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Nariya ChoDepartment of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Woo Kyung MoonDepartment of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea. moonwk@snu.ac.kr.
Gi Jeong CheonDepartment of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea. larrycheon@gmail.com.
Seoul National University Hospital · KRSeoul National University · KRKyungpook National University Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOncotype DX, a 21-gene expression assay, provides a recurrence score (RS) which predicts prognosis and the benefit from adjuvant chemotherapy in patients with early-stage, estrogen receptor-positive (ER-positive), and human epidermal growth factor receptor 2-negative (HER2-negative) invasive breast cancer. However, Oncotype DX tests are expensive and not readily available in all institutions. The purpose of this study was to investigate whether metabolic parameters on (18)F-FDG PET/CT are associated with the Oncotype DX RS and whether (18)F-FDG PET/CT can be used to predict the Oncotype DX RS.

methodsThe study group comprised 38 women with stage I/II, ER-positive/HER2-negative invasive breast cancer who underwent pretreatment (18)F-FDG PET/CT and Oncotype DX testing. On PET/CT, maximum (SUVmax) and average standardized uptake values, metabolic tumor volume, and total lesion glycolysis were measured. Partial volume-corrected SUVmax (PVC-SUVmax) determined using the recovery coefficient method was also evaluated. Oncotype DX RS (0 - 100) was categorized as low (<18), intermediate (18 - 30), or high (≥31). The associations between metabolic parameters and RS were analyzed. Multivariate logistic regression was used to identify significant independent predictors of low versus intermediate-to-high RS.

resultsOf the 38 patients, 22 (58 %) had a low RS, 13 (34 %) had an intermediate RS, and 3 (8 %) had a high RS. In the analysis with 38 index tumors, PVC-SUVmax was higher in tumors in patients with intermediate-to-high RS than in those with low RS (5.68 vs. 4.06; P = 0.067, marginally significant). High PVC-SUVmax (≥4.96) was significantly associated with intermediate-to-high RS (odds ratio, OR, 10.556; P = 0.004) in univariate analysis. In multivariate analysis with clinicopathologic factors, PVC-SUVmax ≥4.96 (OR 8.459; P = 0.013) was a significant independent predictor of intermediate-to-high RS.

conclusionsHigh PVC-SUVmax on (18)F-FDG PET/CT was significantly associated with an intermediate-to-high Oncotype DX RS. PVC metabolic parameters on (18)F-FDG PET/CT can be used to predict the Oncotype DX RS in patients with early-stage, ER-positive/HER2-negative breast cancer.

Indexed as

AdultBiological TransportBiomarkers, TumorBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleFluorodeoxyglucose F18HumansMiddle AgedNeoplasm InvasivenessNeoplasm StagingPositron Emission Tomography Computed TomographyPrognosisReceptors, EstrogenRecurrenceTumor BurdenBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesFluorodeoxyglucose F18Receptors, Estrogen18F-FDG PET/CTBreast cancerOncotype DXOncotype DX recurrence scorePartial volume correctionRecovery coefficient

Identifiers

PMID27209424
OpenAlexW2405951173

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.